특발성 폐섬유증 및 진행성 폐섬유증의 최신 진료 지침 소개
New Guidelines for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Idiopathic pulmonary fibrosis (IPF) is the most common and fatal idiopathic interstitial pneumonia and is characterized by chronic progressive pulmonary fibrosis of indeterminate etiology. In 2018, the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society published joint clinical practice guidelines for IPF. The guidelines require exclusion of known causes of interstitial lung disease and identification of a radiological and/or pathologic pattern of usual interstitial pneumonia (UIP). The diagnosis of IPF is a multidisciplinary process, involving pulmonologists, radiologists, pathologists and, if necessary, experts in other medical fields. The 2022 guidelines for IPF revisit and clarify the radiological and pathological features of UIP. In addition, recommendations regarding transbronchial lung cryobiopsy, antacid medication, and antireflux surgery are revised or established based on up-to-date evidence in the 2022 guidelines. The new guidelines also encompass the definition and treatment of progressive pulmonary fibrosis (PPF). PPF comprises diverse fibrotic interstitial lung diseases other than IPF, which progress despite standard treatment. The diagnosis of PPF is based on symptoms, physiologic evidence, and radiologic evidence of progression. The use of nintedanib was suggested for patients with PPF other than IPF who are unresponsive to standard treatment. This review introduces and discusses the recommendations for the diagnosis and treatment of IPF and PPF in the new international guidelines.
Abstract
Idiopathic pulmonary fibrosis (IPF) is the most common and fatal idiopathic interstitial pneumonia and is characterized by chronic progressive pulmonary fibrosis of indeterminate etiology. In 2018, the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society published joint clinical practice guidelines for IPF. The guidelines require exclusion of known causes of interstitial lung disease and identification of a radiological and/or pathologic pattern of usual interstitial pneumonia (UIP). The diagnosis of IPF is a multidisciplinary process, involving pulmonologists, radiologists, pathologists and, if necessary, experts in other medical fields. The 2022 guidelines for IPF revisit and clarify the radiological and pathological features of UIP. In addition, recommendations regarding transbronchial lung cryobiopsy, antacid medication, and antireflux surgery are revised or established based on up-to-date evidence in the 2022 guidelines. The new guidelines also encompass the definition and treatment of progressive pulmonary fibrosis (PPF). PPF comprises diverse fibrotic interstitial lung diseases other than IPF, which progress despite standard treatment. The diagnosis of PPF is based on symptoms, physiologic evidence, and radiologic evidence of progression. The use of nintedanib was suggested for patients with PPF other than IPF who are unresponsive to standard treatment. This review introduces and discusses the recommendations for the diagnosis and treatment of IPF and PPF in the new international guidelines.
참고문헌 (41)
- American Thoracic Society, "American Thoracic Society", European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. This joint statement of the American Thoracic Society(ATS), and the European Respiratory Society(ERS)was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001, 2002, pp.165, 277~304
- 박성우, "Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 1. Introduction", Tuberculosis and Respiratory Diseases, 82(4), pp.269~276 (2019), 대한결핵및호흡기학회[DOI]
- Lederer DJ, "Idiopathic pulmonary fibrosis", N Engl J Med, 378, pp.1811~1823 (2018)
- 이상훈, "Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 2. Idiopathic Pulmonary Fibrosis", Tuberculosis and Respiratory Diseases, 82(2), pp.102~117 (2019), 대한결핵및호흡기학회[DOI]
- Ley B, "Clinical course and prediction of survival in idiopathic pulmonary fibrosis", Am J Respir Crit Care Med, 183, pp.431~440 (2011)
- Richeldi L, "Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis", N Engl J Med, 370, pp.2071~2082 (2014)
- King TE Jr, "A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis", N Engl J Med, 370, pp.2083~2092 (2014)
- Lancaster L, "Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib : pooled data from six clinical trials", BMJ Open Respir Res, 6, pp.e000397~ (2019)
- Cho HK, "Clinical characteristics and prognostic factors of fibrotic nonspecific interstitial pneumonia", Ther Adv Respir Dis, 16, pp.17534666221089468~ (2022)
- De Sadeleer LJ, "Effects of corticosteroid treatment and antigen avoidance in a large hypersensitivity pneumonitis cohort : a single-centre cohort study", J Clin Med, 8, pp.14~ (2018)
- Tashkin DP, "Cyclophosphamide versus placebo in scleroderma lung disease", N Engl J Med, 354, pp.2655~2666 (2006)
- Kwon BS, "Progressive fibrosing interstitial lung disease : prevalence and clinical outcome", Respir Res, 22, pp.282~ (2021)
- Brown KK, "The natural history of progressive fibrosing interstitial lung diseases", Eur Respir J, 55, pp.2000085~ (2020)
- Flaherty KR, "Nintedanib in progressive fibrosing interstitial lung diseases", N Engl J Med, 381, pp.1718~1727 (2019)
- Behr J, "Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis(RELIEF) : a double-blind, randomised, placebo-controlled, phase 2b trial", Lancet Respir Med, 9, pp.476~486 (2021)
- Raghu G, "Diagnosis of idiopathic pulmonary fibrosis. An official ATS", ERS, ALAT clinical practice guideline, pp.Am J Respir Crit Care Med, 2018[DOI]
- Raghu G, "Idiopathic pulmonary fibrosis(an update)and progressive pulmonary fibrosis in adults : an official ATS", ERS, ALAT clinical practice guideline, pp.Am J Respir Crit Care Med, 2022[DOI]
- Kheir F, "Transbronchial lung cryobiopsy in patients with interstitial lung disease : a systematic review", Ann Am Thorac Soc, 19, pp.1193~1202 (2022)
- Troy LK, "Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis(COLDICE) : a prospective, comparative study", Lancet Respir Med, 8, pp.171~181 (2020)
- Romagnoli M, "Poor concordance between sequential transbronchial lung cryobiopsy and surgical lung biopsy in the diagnosis of diffuse interstitial lung diseases", Am J Respir Crit Care Med, 199, pp.1249~1256 (2019)
- Raghu G, "An official ATS", ERS, ALAT statement : idiopathic pulmonary fibrosis : evidence-based guidelines for diagnosis and management, pp.Am J Respir Crit Care Med, 2011[DOI]
- Raghu G, "An official ATS", ERS, ALAT clinical practice guideline : treatment of idiopathic pulmonary fibrosis. An update of the 2011clinical practice guideline, pp.Am J Respir Crit Care Med, 2015[DOI]
- Raghu G, "High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis", Eur Respir J, 27, pp.136~142 (2006)
- Tossier C, "Hiatal hernia on thoracic computed tomography in pulmonary fibrosis", Eur Respir J, 48, pp.833~842 (2016)
- Lee JS, "Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis", Am J Respir Crit Care Med, 184, pp.1390~1394 (2011)
- Lee JS, "Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis : an analysis of data from three randomised controlled trials", Lancet Respir Med, 1, pp.369~376 (2013)
- Khor YH, "Antacid medication and antireflux surgery in patients with idiopathic pulmonary fibrosis : a systematic review and meta-analysis", Ann Am Thorac Soc, 19, pp.833~844 (2022)
- Raghu G, "Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis(WRAP-IPF) : a multicentre, randomised, controlled phase 2 trial", Lancet Respir Med, 6, pp.707~714 (2018)
- Linden PA, "Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation", J Thorac Cardiovasc Surg, 131, pp.438~446 (2006)
- Maher TM, "Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease : a double-blind, randomised, placebo-controlled, phase 2 trial", Lancet Respir Med, 8, pp.147~157 (2020)
- Torrisi SE, "Outcomes and incidence of PF-ILD according to different definitions in a real-world setting", Front Pharmacol, 12, pp.790204~ (2021)
- George PM, "Progressive fibrosing interstitial lung disease : clinical uncertainties, consensus recommendations, and research priorities", Lancet Respir Med, 8, pp.925~934 (2020)
- Karimi-Shah BA, "Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib", N Engl J Med, 372, pp.1189~1191 (2015)
- du Bois RM, "Forced vital capacity in patients with idiopathic pulmonary fibrosis : test properties and minimal clinically important difference", Am J Respir Crit Care Med, 184, pp.1382~1389 (2011)
- Collard HR, "Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis", Am J Respir Crit Care Med, 168, pp.538~542 (2003)
- Ryerson CJ, "Prevalence and prognosis of unclassifiable interstitial lung disease", Eur Respir J, 42, pp.750~757 (2013)
- Yamauchi H, "Clinical course and changes in high-resolution computed tomography findings in patients with idiopathic pulmonary fibrosis without honeycombing", PLoS One, 11, pp.e0166168~ (2016)
- Jacob J, "Serial CT analysis in idiopathic pulmonary fibrosis : comparison of visual features that determine patient outcome", Thorax, 75, pp.648~654 (2020)
- Akira M, "Long-term follow-up high-resolution CT findings in non-specific interstitial pneumonia", Thorax, 66, pp.61~65 (2011)
- Lee HY, "High-resolution CT findings in fibrotic idiopathic interstitial pneumonias with little honeycombing : serial changes and prognostic implications", AJR Am J Roentgenol, 199, pp.982~989 (2012)
- Ghazipura M, "Pirfenidone in progressive pulmonary fibrosis : a systematic review and meta-analysis", Ann Am Thorac Soc, 19, pp.1030~1039 (2022)